Is VKTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VKTX. It does not provide personalized investment advice.

VKTX (Viking Therapeutics) Stock Analysis - Financials

Viking Therapeutics (VKTX) is a publicly traded Healthcare sector company. As of July 5, 2026, VKTX trades at $37.44 with a market cap of $4.35B and a P/E ratio of -11.74. VKTX moved -0.13% today. Year to date, VKTX is +6.00%; over the trailing twelve months it is +35.06%. Its 52-week range spans $18.92 to $68.87. Analyst consensus is strong buy with an average price target of $92.91. Rallies surfaces VKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are VKTX's key financials?

VKTX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VKTX recently traded at $37.44. Market cap is $4.35B. P/E ratio is -11.74. Revenue is $0.

VKTX Key Metrics

Key financial metrics for VKTX
Metric	Value
Price	$37.44
Market Cap	$4.35B
P/E Ratio	-11.74
EPS	$-3.19
Dividend Yield	0.00%
52-Week High	$68.87
52-Week Low	$18.92
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-359.64M
Gross Margin	0.00%

VKTX Analyst Consensus

13 analysts cover VKTX: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $92.91.

Common questions about VKTX

What are VKTX's key financials?: VKTX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VKTX recently traded at $37.44. Market cap is $4.35B. P/E ratio is -11.74. Revenue is $0.
Is VKTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VKTX. It does not provide personalized investment advice.